A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension

Journal of Human Hypertension

Volumn 28, Issue 1, 2014, Pages 3-9

  Byrd, J B ^a   Brook, R D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aldosterone; Mineralocorticoid receptor; Mineralocorticoid receptor antagonists; Mineralocorticoids; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; AMILORIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CORTISONE; DEOXYCORTICOSTERONE; DIURETIC AGENT; EPLERENONE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SODIUM; SPIRONOLACTONE;

ADD ON THERAPY; ADIPOCYTE; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ALDOSTERONE URINE LEVEL; DRUG EFFICACY; HUMAN; HYPERTENSION; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; OBESITY; PLASMA RENIN ACTIVITY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SODIUM BLOOD LEVEL; SYMPATHETIC NERVE; WAIST CIRCUMFERENCE; COMPLICATION; EVIDENCE BASED MEDICINE; METABOLISM; PATHOPHYSIOLOGY;

ALDOSTERONE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MINERALOCORTICOIDS; OBESITY;

EID: 84889665065     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.42     Document Type: Review

References (50)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307(5): 491-497.
2. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension 2000; 35(4): 1009-1015.
3. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162(16): 1867-1872.
4. Garrison RJ, Kannel WB, Stokes 3rd J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16(2): 235-251.
5. Neter JE, Stam BE, Kok FJ, Robbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884.
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403-1419.
7. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150(11): 776-783.
8. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012; 25(5): 514-523.
9. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation 2002; 106(20): 2533-2536.
10. Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circ Res 1988; 62(6): 1259-1262.
11. Yiannikouris F, Karounos M, Charnigo R, English VL, Rateri DL, Daugherty A et al. Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 2012; 302(2): R244-R251.
12. Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptideforming enzymes of 3T3-F442A adipocytes. Am J Physiol 1993; 264(6 Pt 1): C1570-C1576.
13. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17(4): 555-560.
14. Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2008; 295(3): R781-R788.
15. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 1994; 35(8): 1378-1385.
16. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138(4): 1512-1519.
17. Weiland F, Verspohl EJ. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 2008; 40(11): 760-766.
18. Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 2007; 292(1): R274-R282.
19. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59(5): 1069-1078.
20. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE et al. Cloning of human mineralocorticoid receptor complementary-DNA-structural and functional kinship with the glucocorticoid receptor. Science 1987; 237(4812): 268-275.
21. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H et al. Modification of mineralocorticoid receptor function by Rac1 GT Pase: implication in proteinuric kidney disease. Nat Med 2008; 14(12): 1370-1376.
22. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S et al. Rac1 GT Pase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121(8): 3233-3243.
23. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A et al. Human adipocytes secrete mineralocorticoid- releasing factors. Proc Natl Acad Sci USA 2003; 100(24): 14211-14216.
24. Jeon JH, Kim KY, Kim JH, Baek A, Cho H, Lee YH et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008; 22(5): 1502-1511.
25. O'Seaghdha CM, Hwang SJ, Vasan RS, Larson MG, Hoffmann U, Wang TJ et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the framingham heart study. BMC Endocr Disord 2012; 12: 3.
26. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999; 7(4): 355-362.
27. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24(3-4): 789-796.
28. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92(11): 4472-4475.
29. Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessi-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens 2012; 25(7): 818-826.
30. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46(3): 481-487.
31. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49(4): 839-845.
32. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2(6): 462-468.
33. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-152.
34. Hiramatsu K, Yamada T, Ichikawa K, Izumiyama T, Nagata H. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc 1981; 29(1): 25-30.
35. Andronico G, Cottone S, Mangano MT, Ferraro-Mortellaro R, Baiardi G, Grassi N et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001; 25(2): 239-242.
36. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351(1): 33-41.
37. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48(2): 239-245.
38. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91(2): 454-459.
39. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49(3): 704-711.
40. Mule G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C et al. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens 2008; 21(9): 1055-1061.
41. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93(7): 2566-2571.
42. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304(16): 930-933.
43. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986; 57(8): 613-618.
44. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321(9): 580-585.
45. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
46. Dall'Asta C, Vedani P, Manunta P, Pizzocri P, Marchi M, Paganelli M et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis 2009; 19(2): 110-114.
47. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007; 116(3): 268-275.
48. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57(6): 1069-1075.
49. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16(11 Pt 1): 925-930.
50. Heshka J, Ruzicka M, Hiremath S, McCormick BB. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J Am Soc Hypertens 2010; 4(6): 295-301.